Nexien Biopharma Stock Today
| NXEN Stock | USD 0.01 0.00 0.00% |
Performance10 of 100
| Odds Of DistressOver 73
|
Nexien Biopharma is selling at 0.014 as of the 4th of December 2024; that is No Change since the beginning of the trading day. The stock's open price was 0.014. Nexien Biopharma has a very high chance of experiencing financial distress in the next few years of operation. However, it had a very ok returns during the last 90 days. Equity ratings for Nexien Biopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 15th of December 2022 and ending today, the 4th of December 2024. Click here to learn more.
Nexien BioPharma, Inc. operates as a pharmaceutical company. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.. The company has 62.77 M outstanding shares. More on Nexien Biopharma
Moving against Nexien Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Nexien Pink Sheet Highlights
| Old Names | [APRICUS BIOSCIENCES, APRICUS BIOSCIENCES (NXEN.SG), APRICUS BIOSCIENCES - Frankfurt Stock Exchang] |
| Business Concentration | Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Nexien Biopharma [NXEN] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.95 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nexien Biopharma's market, we take the total number of its shares issued and multiply it by Nexien Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Nexien Biopharma conducts business under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 62.77 M outstanding shares.
Nexien Biopharma currently holds about 116.9 K in cash with (75.14 K) of positive cash flow from operations.
Check Nexien Biopharma Probability Of Bankruptcy
Ownership AllocationNexien Biopharma maintains a total of 62.77 Million outstanding shares. Nexien Biopharma holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Nexien Ownership Details
Nexien Biopharma Risk Profiles
| Mean Deviation | 19.95 | |||
| Semi Deviation | 19.71 | |||
| Standard Deviation | 34.64 | |||
| Variance | 1199.81 |
Nexien Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Nexien Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Manager Now
Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital |
| All Next | Launch Module |
Nexien Biopharma Corporate Management
| Joseph Morgan | Consultant | Profile | |
| Esq JD | Chief Officer | Profile | |
| Richard Greenberg | CEO, Founder | Profile | |
| Evan CPA | Chief Officer | Profile | |
| Paul Wilkenson | Consultant | Profile | |
| Linda Klumpers | Consultant | Profile |
Other Information on Investing in Nexien Pink Sheet
Nexien Biopharma financial ratios help investors to determine whether Nexien Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nexien with respect to the benefits of owning Nexien Biopharma security.